Insight Molecular Diagnostics Inc. Common Stock (IMDX)
IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES
- Headquarters
- United States
- Employees
- 58
- Market Cap
- $149M
About Insight Molecular Diagnostics Inc. Common Stock
Insight Molecular Diagnostics Inc is a pioneering diagnostics technology company whose mission is to democratize access to novel molecular diagnostic testing to improve patient outcomes. The Company's flagship technology quantifies a molecular biomarker known as donor-derived cell-free DNA (dd-cfDNA). It is also in the process of rebranding its RUO test kit, GraftAssure, as GraftAssureIQ, and rebranding its future in-vitro diagnostic (IVD) test kit as GraftAssureDx. The company geographically operates in the United States, the United Kingdom, Europe, and the Asia-Pacific regions, with maximum revenue generated from the USA.
SentiSense also tracks daily options readings for Insight Molecular Diagnostics Inc. Common Stock: IV rank, put/call percentile, 25-delta skew, open-interest walls, and unusually active contracts, each measured against the stock's own history. Sign in to view them.
Insight Molecular Diagnostics Inc. Common Stock stock analysis, sentiment tracking, and market intelligence on SentiSense.